O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Titel:
O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Auteur:
Wyrwicz, L. Oh, D. Weber, P. Bai, Y. Ryu, M. Lee, J. Rivera, F. Alves, G. Vasconcelos Garrido, M. Shiu, K. Fernandez, M. Gonzalez Li, J. Lowery, M. Çil, T. Cruz, F. Qin, S. Yin, L. Bordia, S. Bhagia, P. Rha, S.